Pharmaceuticals Malaysia

Malaysia Antibody-Drug Conjugates Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Malaysia Antibody-Drug Conjugates Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $21.3 Mn Placeholder estimate
Estimate 2025 $25.1 Mn 0.2% of the global market
Projected 2034 $112.2 Mn 346.9% Adds $87.1 Mn over 9 forecast years
CAGR 2025–2034 18.1% Faster than 82% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Malaysia is 0.17% of the global market.
  • In APAC, the largest is China at $1.20 Bn.
  • Fastest growing: India at 21.1% a year.
  • Malaysia ranks 7th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$87.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Antibody-Drug Conjugates Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $21.3 Mn — —
2025 (base) $25.1 Mn +$3.8 Mn —
2026 (forecast) $29.6 Mn +$4.5 Mn +18.1%
2027 (forecast) $35.0 Mn +$5.4 Mn +39.5%
2028 (forecast) $41.4 Mn +$6.3 Mn +64.7%
2029 (forecast) $48.8 Mn +$7.5 Mn +94.5%
2030 (forecast) $57.7 Mn +$8.8 Mn +129.7%
2031 (forecast) $68.1 Mn +$10.4 Mn +171.3%
2032 (forecast) $80.4 Mn +$12.3 Mn +220.4%
2033 (forecast) $95.0 Mn +$14.6 Mn +278.4%
2034 (forecast) $112.2 Mn +$17.2 Mn +346.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Malaysia Antibody-Drug Conjugates Market Analysis at a glance
Market size, 2025$25.1 Mn placeholder estimate
Forecast, 2034$112.2 Mn placeholder estimate
Growth (CAGR), 2025–203418.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAstraZeneca, Daiichi Sankyo Company, Pfizer Inc., Gilead Sciences, Inc., Roche and 1 more (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials8 in MalaysiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia Antibody-Drug Conjugates Market Analysis Executive Summary

Antibody-drug conjugates join a cancer-targeting antibody to a strong cancer drug, delivering treatment straight to tumour cells.

Key segments of the antibody-Drug Conjugates market include target (HER2, TROP2 and Nectin-4) and indication (Breast Cancer, Lung Cancer and Bladder Cancer).

Bar chart: Malaysia Antibody-Drug Conjugates market size, 2024–2034, placeholder estimates. $21.3 Mn in 2024, $25.1 Mn in 2025 and $112.2 Mn in 2034, 18.1% CAGR.
Malaysia Antibody-Drug Conjugates market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia Antibody-Drug Conjugates Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the antibody-Drug Conjugates market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the antibody-Drug Conjugates market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the antibody-Drug Conjugates market, especially in low- and middle-income countries.

Competitive Landscape for Antibody-Drug Conjugates Market in Malaysia

The antibody-Drug Conjugates market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Antibody-Drug Conjugates Market in Malaysia

Antibody-Drug Conjugates in Malaysia: rules, payment and research

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2] ClinicalTrials.gov lists 8 studies on Antibody-Drug Conjugates that are recruiting, active or about to start in Malaysia.⁠[3]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antibody-Drug Conjugates. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antibody-Drug Conjugates right now, from free public sources.

Clinical trials

8 active trials in Malaysia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 21 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Daiichi Sankyo Company 8 active trials on ClinicalTrials.gov (opens in a new tab)
  3. BioNTech 7 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Hansoh BioMedical R&D Company 7 active trials on ClinicalTrials.gov (opens in a new tab)
  5. MediLink Therapeutics (Suzhou) Co., Ltd. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antibody-Drug Conjugates in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 7th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 7th highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 10th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Antibody-Drug Conjugates market in Malaysia?
Placeholder estimate: about $25.1 Mn in 2025, rising to about $112.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Antibody-Drug Conjugates market in Malaysia growing?
Placeholder estimate: about 18.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Antibody-Drug Conjugates market report cover?
The report splits the market by target (HER2, TROP2, Nectin-4, CD30 and more), indication (Breast Cancer, Lung Cancer, Bladder Cancer, Blood Cancers) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Antibody-Drug Conjugates market?
Key players include AstraZeneca, Daiichi Sankyo Company, Pfizer Inc., Gilead Sciences, Inc., Roche and AbbVie Inc..
What is driving the Antibody-Drug Conjugates market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the antibody-Drug Conjugates market. Faster approvals and new combinations are improving survival.
Who regulates Antibody-Drug Conjugates in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How many clinical trials on Antibody-Drug Conjugates are running in Malaysia?
8 studies are recruiting, active or about to start in Malaysia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
How much research is published on Antibody-Drug Conjugates?
PubMed lists 5,522 papers on Antibody-Drug Conjugates added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Malaysia

See all

Related on oncology

See the topic